Capstan Therapeutics to Participate in Cowen 44th Annual Health Care Conference 

SAN DIEGO, March 1, 2024 – Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), today announced that Capstan management will participate in the upcoming Cowen 44th Annual Health Care Conference, being held between March 4-6, 2024 in Boston, MA. Capstan will be hosting one-on-one meetings with investors on Monday, March 4.

About Capstan Therapeutics, Inc. (
Capstan is a biotechnology company with a mission to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. The core platform technology comprises proprietary targeted lipid nanoparticles (tLNP) that are composed of LNPs conjugated with a recombinant protein binder, such as a monoclonal antibody. tLNPs are designed to deliver payloads, including mRNA or gene editing tools, capable of reprogramming specific cell types in vivo. The platform technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. For more information, please visit and follow us on LinkedIn.

Miguel Arcinas
Senior Vice President of Corporate Development
Capstan Therapeutics
[email protected]

Rhiannon Jeselonis
Ten Bridge Communications
[email protected]

Back to News